so why are they putting a vote to stockholders? robin smith has a great point that the stock has been run into the ground the past three years. other companies making zero money, and without the intellectual property of this company have been faring far better. i can see why some stockholders blame management. at a MINIMUM, this stock should be at least a buck -- not in the pennies.
perhaps. that looks good on paper. but there's a reason the stock plummeted.
how does the science affect the other potential products with the strategic alliances? that's the big question. right now -- unless this clinical hold is the FDA being overly cautious -- it looks like the best best for stockholders is an acquisition by a partner that sees value in the other parts.
another big question is whether the recent financing will be scuttled. anyone who can give any updates or insight, please do.